Biocon has reported its financial results for the quarter and full year ending March 31, 2026. The company signals a major inflection point, having completed its corporate reorganization and successfully transitioning from a heavy investment phase into a period of execution and value creation. With a strengthened balance sheet and a unified global biopharma platform, the firm is now focusing on improving operational efficiency, scaling its biosimilars business, and enhancing profitability across all segments.
FY26 Financial Performance
For the full fiscal year 2026, Biocon achieved total revenue of ₹17,270 crore, representing a 14% growth on an adjusted basis. The company reported an annual EBITDA of ₹3,798 crore with a margin of 22%. The fiscal year marks a transition for the company as it shifts focus from capital-intensive capacity building to optimizing utilization and expanding margins.
Quarterly Highlights: Q4 FY26
During the final quarter (January–March 2026), Biocon recorded total revenue of ₹4,569 crore, a 10% increase year-over-year. EBITDA for the quarter stood at ₹1,073 crore, reflecting a 23% margin. The net profit, before exceptional items, was reported at ₹179 crore, marking a 64% growth compared to the same period in the previous year.
Segment Performance
- Biosimilars: This segment continues to be a key driver, with quarterly revenue reaching ₹2,756 crore, up 12% year-over-year. The company noted strong performance in North America and steady growth in emerging markets.
- Generics: Revenue for the quarter was ₹847 crore, a 13% growth on an adjusted basis, driven primarily by successful gLiraglutide launches in Europe.
- CRDMO: The research and manufacturing services segment reported quarterly revenue of ₹1,037 crore. The segment remains resilient, underscored by the recent extension of the BMS partnership through 2035.
Strategic Outlook
Looking ahead to FY27, the management team remains committed to scaling its recent biosimilars launches to drive further operating leverage. The company expects performance to strengthen progressively throughout the year, with a clear mandate to improve Return on Capital Employed (RoCE) and continue its trajectory of sustainable long-term value creation.
Source: BSE
